Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?
From its discovery, hepcidin has generated many hopes in terms of diagnosis and management of a wide variety of iron-related diseases. However, in clinical use its accurate quantification remains a challenge due to the limited sensitivity, specificity or reproducibility of the techniques described....
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-06-01
|
Series: | EuPA Open Proteomics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2212968514000087 |
id |
doaj-f02e2c48a2384a778557fb5812e52ce8 |
---|---|
record_format |
Article |
spelling |
doaj-f02e2c48a2384a778557fb5812e52ce82020-11-24T20:59:20ZengElsevierEuPA Open Proteomics2212-96852014-06-013C606710.1016/j.euprot.2014.02.004Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?Constance Delaby0Jérôme Vialaret1Pauline Bros2Audrey Gabelle3Thibaud Lefebvre4Hervé Puy5Christophe Hirtz6Sylvain Lehmann7CHU Montpellier, Institut de Recherche en Biothérapie, Hôpital St Eloi, Laboratoire de Biochimie Protéomique Clinique et CCBHM, Montpellier F-34000, FranceCHU Montpellier, Institut de Recherche en Biothérapie, Hôpital St Eloi, Laboratoire de Biochimie Protéomique Clinique et CCBHM, Montpellier F-34000, FranceCHU Montpellier, Institut de Recherche en Biothérapie, Hôpital St Eloi, Laboratoire de Biochimie Protéomique Clinique et CCBHM, Montpellier F-34000, FranceCHU Montpellier, Institut de Recherche en Biothérapie, Hôpital St Eloi, Laboratoire de Biochimie Protéomique Clinique et CCBHM, Montpellier F-34000, FranceCentre de Recherche sur l’Inflammation (CRI)/UMR 1149 INSERM – Université Paris Diderot, FranceCentre de Recherche sur l’Inflammation (CRI)/UMR 1149 INSERM – Université Paris Diderot, FranceCHU Montpellier, Institut de Recherche en Biothérapie, Hôpital St Eloi, Laboratoire de Biochimie Protéomique Clinique et CCBHM, Montpellier F-34000, FranceCHU Montpellier, Institut de Recherche en Biothérapie, Hôpital St Eloi, Laboratoire de Biochimie Protéomique Clinique et CCBHM, Montpellier F-34000, FranceFrom its discovery, hepcidin has generated many hopes in terms of diagnosis and management of a wide variety of iron-related diseases. However, in clinical use its accurate quantification remains a challenge due to the limited sensitivity, specificity or reproducibility of the techniques described. In this work, we adapted a highly specific and quantitative mass spectrometry method based on selected reaction monitoring (SRM) to measure hepcidin. Our objective was to adapt the feasibility and reproducibility of the workflow to a clinical environment. Analytical validation was performed according to ISO 15189 norms for determining the limit of detection (LOD, 2 ng/mL), limit of quantification (LOQ, 6 ng/mL), repeatability, reproducibility and linearity (up to 200 ng/mL). Using the serum of patients with various iron-related diseases we compared our SRM detection method to the well-characterized competitive ELISA (cELISA) test. The two methods were commutable (Bland–Altman plot) and we found a positive and significant correlation (r2 = 0.96, Pearson correlation coefficient p < 0.001) between both methods, although the absolute concentration determined is different from factor 5. The validation of our SRM method encourages us to propose it as an alternative approach for accurate determination of hepcidin in human samples for clinical diagnosis, follow-up and management of iron-related diseases.http://www.sciencedirect.com/science/article/pii/S2212968514000087HepcidinIron deficiencyMass spectrometryELISA |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Constance Delaby Jérôme Vialaret Pauline Bros Audrey Gabelle Thibaud Lefebvre Hervé Puy Christophe Hirtz Sylvain Lehmann |
spellingShingle |
Constance Delaby Jérôme Vialaret Pauline Bros Audrey Gabelle Thibaud Lefebvre Hervé Puy Christophe Hirtz Sylvain Lehmann Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job? EuPA Open Proteomics Hepcidin Iron deficiency Mass spectrometry ELISA |
author_facet |
Constance Delaby Jérôme Vialaret Pauline Bros Audrey Gabelle Thibaud Lefebvre Hervé Puy Christophe Hirtz Sylvain Lehmann |
author_sort |
Constance Delaby |
title |
Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job? |
title_short |
Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job? |
title_full |
Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job? |
title_fullStr |
Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job? |
title_full_unstemmed |
Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job? |
title_sort |
clinical measurement of hepcidin-25 in human serum: is quantitative mass spectrometry up to the job? |
publisher |
Elsevier |
series |
EuPA Open Proteomics |
issn |
2212-9685 |
publishDate |
2014-06-01 |
description |
From its discovery, hepcidin has generated many hopes in terms of diagnosis and management of a wide variety of iron-related diseases. However, in clinical use its accurate quantification remains a challenge due to the limited sensitivity, specificity or reproducibility of the techniques described. In this work, we adapted a highly specific and quantitative mass spectrometry method based on selected reaction monitoring (SRM) to measure hepcidin. Our objective was to adapt the feasibility and reproducibility of the workflow to a clinical environment. Analytical validation was performed according to ISO 15189 norms for determining the limit of detection (LOD, 2 ng/mL), limit of quantification (LOQ, 6 ng/mL), repeatability, reproducibility and linearity (up to 200 ng/mL). Using the serum of patients with various iron-related diseases we compared our SRM detection method to the well-characterized competitive ELISA (cELISA) test. The two methods were commutable (Bland–Altman plot) and we found a positive and significant correlation (r2 = 0.96, Pearson correlation coefficient p < 0.001) between both methods, although the absolute concentration determined is different from factor 5. The validation of our SRM method encourages us to propose it as an alternative approach for accurate determination of hepcidin in human samples for clinical diagnosis, follow-up and management of iron-related diseases. |
topic |
Hepcidin Iron deficiency Mass spectrometry ELISA |
url |
http://www.sciencedirect.com/science/article/pii/S2212968514000087 |
work_keys_str_mv |
AT constancedelaby clinicalmeasurementofhepcidin25inhumanserumisquantitativemassspectrometryuptothejob AT jeromevialaret clinicalmeasurementofhepcidin25inhumanserumisquantitativemassspectrometryuptothejob AT paulinebros clinicalmeasurementofhepcidin25inhumanserumisquantitativemassspectrometryuptothejob AT audreygabelle clinicalmeasurementofhepcidin25inhumanserumisquantitativemassspectrometryuptothejob AT thibaudlefebvre clinicalmeasurementofhepcidin25inhumanserumisquantitativemassspectrometryuptothejob AT hervepuy clinicalmeasurementofhepcidin25inhumanserumisquantitativemassspectrometryuptothejob AT christophehirtz clinicalmeasurementofhepcidin25inhumanserumisquantitativemassspectrometryuptothejob AT sylvainlehmann clinicalmeasurementofhepcidin25inhumanserumisquantitativemassspectrometryuptothejob |
_version_ |
1716782780718776320 |